Ziprasidone (Geodon) is a relatively new atypical antipsychotic medication with a unique pharmacological profile. It is indicated for the treatment of schizophrenia, but has also often been used off-label for other uses. This review summarizes its important properties, specifically the pharmacodynamic parameters, receptor-binding profile and relevance to clinical outcomes, side effects, and potential for drug-drug interactions and established clinical indications. Novel therapeutic applications and relevant clinical trials or reports are also examined. The authors review the current market and speculate on likely changes in 5 years.
No takes yet. Share an insight, caveat, or question.
Ballas et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: